IBL International has entered a strategic collaboration with healthcare company Grifols to develop biomarker panels for speciality diagnostics.
Through this partnership, IBL will develop the panels structured for random access on Grifols’ single molecule counting (SMC) platform. It is set to manufacture and supply the products in accordance with a master supply agreement.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This initiative combines IBL’s speciality diagnostic assay development “expertise” with Grifols’ diagnostic instrumentation “leadership”.
Grifols’ random-access technology enables labs to immediately process tests, removing the batching time delay.
These biomarker panels are being developed in response to customer feedback to meet the lab and patient requirements.
According to IBL, speciality diagnostics frequently function outside of the core lab’s automated workflows, needing equipment and processes to tackle low-volume, high-value tests.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBy integrating several speciality diagnostic parameters into one workflow, the collaboration aims to streamline these processes.
Grifols diagnostic operations and strategy senior vice-president Guillermo Marco-Gardoqui said: “Our collaboration with IBL demonstrates our commitment to our strategic plan for developing innovative clinical diagnostic solutions.
“By integrating IBL’s biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care.”
A part of the Tecan Group, IBL International focuses on developing and producing immunoassays and diagnostic solutions while Spain-based Grifols has experience in healthcare, plasma-derived medicines, and diagnostic solutions.
Tecan Life Sciences business division head Mukta Acharya said: “Partnering with Grifols allows us to scale healthcare innovation globally.
“By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in speciality diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.”
